Holen Sie sich die Stockscreener-App
0.9899
11.60%
0.1029
Handel nachbörslich:
.99
0.000100
+0.01%
Schlusskurs vom Vortag:
$0.887
Offen:
$0.89
24-Stunden-Volumen:
694.01K
Relative Volume:
3.64
Marktkapitalisierung:
$111.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.86M
KGV:
-0.553
EPS:
-1.79
Netto-Cashflow:
$-125.29M
1W Leistung:
+10.79%
1M Leistung:
+26.02%
6M Leistung:
+24.05%
1J Leistung:
-41.08%
1-Tages-Spanne:
$0.856
$1.01
1-Wochen-Bereich:
$0.8504
$1.05
52-Wochen-Spanne:
$0.58
$2.485
Allovir Inc Stock (ALVR) Company Profile
Firmenname
Allovir Inc
Sektor
Branche
Telefon
(617) 433-2605
Adresse
1100 WINTER STREET, WALTHAM
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-08-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-24 | Eingeleitet | SVB Leerink | Outperform |
Allovir Inc Aktie (ALVR) Neueste Nachrichten
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact The Gross Law Firm - GuruFocus.com
Discovering Opportunities: AlloVir And 2 Other US Penny Stocks - Simply Wall St
Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Joi - GuruFocus.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely - Simply Wall St
AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to - GuruFocus.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Invest - GuruFocus.com
SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James - GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) - GuruFocus.com
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com
Allovir CEO Diana Brainard sells $7,596 in stock - Investing.com
Allovir's general counsel Edward Miller sells $1,082 in stock By Investing.com - Investing.com South Africa
Allovir's general counsel Edward Miller sells $1,082 in stock - Investing.com
Allovir's chief accounting officer Brett Hagen sells $746 in stock - Investing.com
Allovir CFO Vikas Sinha sells $2,649 in stock - Investing.com
Allovir CFO Vikas Sinha sells $2,649 in stock By Investing.com - Investing.com Canada
Allovir's chief accounting officer Brett Hagen sells $746 in stock By Investing.com - Investing.com UK
BK Virus Infection Market Rising Awareness and Innovations Drive Growth | AlloVir, Amplyx Pharmaceuticals - EIN News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Octagon Capital Advisors LP Increases Stake in AlloVir Inc - GuruFocus.com
Allovir CEO Diana Brainard sells shares to cover tax obligations - Investing.com India
Allovir executive sells shares to cover tax withholding obligations By Investing.com - Investing.com Australia
Allovir executive sells shares to cover tax withholding obligations - Investing.com India
Allovir CEO Diana Brainard sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Allovir general counsel sells $307 worth of shares to cover taxes - Investing.com Australia
Allovir general counsel sells $307 worth of shares to cover taxes By Investing.com - Investing.com South Africa
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. - GlobeNewswire
AlloVir (NASDAQ:ALVR) Shares Up 1% - Defense World
AlloVir, Inc. (NASDAQ:ALVR) Holdings Lowered by Acadian Asset Management LLC - Defense World
AlloVir (NASDAQ:ALVR) Trading 1% Higher - MarketBeat
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm - ForexTV.com
Upward Trajectory: AlloVir Inc (ALVR) Posts a Gaine, Closing at 0.78 - The Dwinnex
Investigation announced for Investors who lost money with - openPR
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR
Head to Head Analysis: Vaxcyte (NASDAQ:PCVX) & AlloVir (NASDAQ:ALVR) - Defense World
Allovir CEO Diana Brainard sells shares worth nearly $4,000 - Investing.com India
Allovir CEO Diana Brainard sells shares worth nearly $4,000 By Investing.com - Investing.com Australia
Allovir executive sells shares to cover tax obligations - Investing.com
Allovir CEO Diana Brainard sells shares worth over $2,300 - Investing.com
Vanguard Group Inc. Lowers Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Price T Rowe Associates Inc. MD Buys 54,900 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
ALVR (AlloVir) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
AlloVir (NASDAQ:ALVR) Posts Earnings Results, Beats Expectations By $0.05 EPS - Defense World
B of A Securities Initiates Coverage of AlloVir (ALVR) with Buy Recommendation - MSN
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
Analyzing Immunovant (NASDAQ:IMVT) & AlloVir (NASDAQ:ALVR) - Defense World
AlloVir Inc (ALVR) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely - Yahoo Finance
Finanzdaten der Allovir Inc-Aktie (ALVR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):